Clinical Research Directory

Inclusion Criteria: * 1\. Able to understand and voluntarily sign the written informed consent form (ICF); 2. Male or female subjects aged 18 to 75 years (inclusive). 3. Patients with NSCLC who have unresectable locally advanced or metastatic disease; 4. At least one measurable lesion, as defined by RECIST 1.1 criteria; 5. ECOG performance status of 0 or 1; 6. Expected survival ≥ 3 months; 7. Adequate function of major organs and bone marrow; 8. Women or man of childbearing potential must use highly effective contraception. Exclusion Criteria: 1. Prior treatment with an EGFR inhibitor or MET inhibitor; 2. Patients with metastases to meninges; with spinal cord compression; symptomatic and unstable brain metastasis; 3. Patients who have taken strong inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of the study drug, or who cannot discontinue the use of strong CYP3A4 inducers and inhibitors during the study; 4. Patients with a history of autoimmune diseases, a history of immunodeficiency, including positive for HIV, or other acquired or congenital immunodeficiency diseases, or a history of organ transplant; 5. Presence of active infection (e.g., subjects are receiving anti-infection therapy); 6. Severe or uncontrolled cardiovascular disorder requiring treatment; 7. Refractory nausea, vomiting, chronic gastrointestinal disease, inability to swallow drugs orally; 8. Women who are pregnant or breastfeeding;